A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group) by Hillmen, P, Richards, S, Smith, A, Hamblin, T, Milligan, D, Catovsky, D

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial by Dearden, C, Wade, R, Else, M, Richards, S, Milligan, D, Hamblin, T, Catovsky, D

The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on th... by Dearden, C, Wade, R, Else, M, Richards, S, Milligan, D, Hamblin, T, Catovsky, D

CAMPATH-1 antibodies in stem-cell transplantation. by Hale, G, Cobbold, S, Novitzky, N, Bunjes, D, Willemze, R, Prentice, H, Milligan, D, MacKinnon, S, Waldmann, H

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid... by Chakrabarti, S, MacDonald, D, Hale, G, Holder, K, Turner, V, Czarnecka, H, Thompson, J, Fegan, C, Waldmann, H, Milligan, D

Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. by Avivi, I, Chakrabarti, S, Milligan, D, Waldmann, H, Hale, G, Osman, H, Ward, K, Fegan, C, Yong, K, Goldstone, A, Linch, D, Mackinnon, S

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation by Ferguson, P, Hills, R, Grech, A, Betteridge, S, Kjeldsen, L, Dennis, M, Vyas, P, Goldstone, A, Milligan, D, Clark, R, Russell, N, Craddock, C

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation. by Mackinnon, S, Kottaridis, P, Perry, A, Chakrabarti, S, Milligan, D, Pettengell, R, Chopra, R, Morgan, G, Hale, G, Waldmann, H, Linch, D, Devereux, S, Goldstone, A

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. by Chakrabarti, S, Milligan, D, Pillay, D, Mackinnon, S, Holder, K, Kaur, N, McDonald, D, Fegan, C, Waldmann, H, Hale, G, Rickinson, A, Steven, N

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. by Chakrabarti, S, Avivi, I, Mackinnon, S, Ward, K, Kottaridis, P, Osman, H, Waldmann, H, Hale, G, Fegan, C, Yong, K, Goldstone, A, Linch, D, Milligan, D

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. by Oscier, D, Dearden, C, Eren, E, Erem, E, Fegan, C, Follows, G, Hillmen, P, Illidge, T, Matutes, E, Milligan, D, Pettitt, A, Schuh, A, Wimperis, J

Results of the randomised phase II NCRI arctic (attenuated dose rituximab with chemotherapy in CLL) trial of low dose rituximab in previously untreated CLL by Munir, T, Cohen, D, Milligan, D, Schuh, A, McParland, L, Chalmers, A, Varghese, A, Rawstron, A, Allsup, D, Marshall, S, Smith, A, Collett, C, Gregory, W, Duncombe, A, Hillmen, P

A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia by Burnett, A, Russell, N, Hills, R, Kell, J, Nielsen, O, Dennis, M, Cahalin, P, Pocock, C, Ali, S, Burns, S, Freeman, S, Milligan, D, Clark, R, behalf of the UK NCRI AML Study Group

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT AND WATCH by Michallet, M, Dreger, P, Sutton, L, Brand, R, Richards, S, van Biezen, A, Sobh, M, Gratwohl, M, Kolbe, K, Dearden, C, Hallek, M, de Witte, T, Niederweiser, D, Leporrier, M, Milligan, D

Autologous Hematopoietic Stem Cell Transplantation (autoHSCT) in CLL: First Results of An EBMT Randomized Trial Comparing Autotransplant Versus Wait and Watch by Michallet, M, Dreger, P, Sutton, L, Brand, R, Richards, S, van Biezen, A, Sobh, M, Gratwohl, A, Kolbe, K, Dearden, C, Hallek, M, de Witte, T, Niederwieser, D, Leporrier, M, Milligan, D

Autologous haematopoietic stem cell transplantation in CLL: first results of an EBMT randomized trial comparing autotransplant versus wait and watch by Michallet, M, Dreger, P, Sutton, L, Brand, R, Richards, S, Van Biezen, A, Sobh, M, Gratwohl, A, Kolbe, K, Dearden, C, Hallek, M, De Witte, T, Niederwieser, D, Leporrier, M, Milligan, D

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. by Peggs, K, Hunter, A, Chopra, R, Parker, A, Mahendra, P, Milligan, D, Craddock, C, Pettengell, R, Dogan, A, Thomson, K, Morris, E, Hale, G, Waldmann, H, Goldstone, A, Linch, D, Mackinnon, S

A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. by Kottaridis, P, Chakraverty, R, Milligan, D, Chakrabarti, S, Robinson, S, Chopra, R, Pettengell, R, Marsh, J, Mahendra, P, Schey, S, Morgan, G, Williams, C, Hale, G, Waldmann, H, Linch, D, Devereux, S, Goldstone, A, Mackinnon, S

High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. by Chakrabarti, S, Mackinnon, S, Chopra, R, Kottaridis, P, Peggs, K, O'Gorman, P, Chakraverty, R, Marshall, T, Osman, H, Mahendra, P, Craddock, C, Waldmann, H, Hale, G, Fegan, C, Yong, K, Goldstone, A, Linch, D, Milligan, D

The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Soci... by Bird, J, Fuge, R, Sirohi, B, Apperley, J, Hunter, A, Snowden, J, Mahendra, P, Milligan, D, Byrne, J, Littlewood, T, Fegan, C, McQuaker, G, Pagliuca, A, Johnson, P, Rahemtulla, A, Morris, C, Marks, D